Curated News
By: NewsRamp Editorial Staff
April 08, 2026
Synbio International Modernizes Trading with DWAC/DRS Approval
TLDR
- Synbio International's DWAC/DRS approval gives investors faster trading and broader market access, positioning them ahead in capitalizing on the company's near-term initiatives.
- DWAC enables electronic share transfers between broker-dealers and transfer agents, while DRS allows direct electronic shareholding on company books, reducing settlement times and transaction friction.
- This modernization improves shareholder accessibility and security, supporting Synbio's mission to develop AI-driven medical diagnostics that enhance healthcare quality and empower providers.
- Synbio International eliminates physical stock certificates with electronic DWAC/DRS systems, making share trading as seamless as digital transactions in today's tech-driven markets.
Impact - Why it Matters
This development matters because it directly impacts investor experience and market efficiency for Synbio International shareholders. By implementing DWAC and DRS systems, the company reduces settlement times from days to potentially hours, lowers transaction costs, and eliminates the risks associated with physical certificate handling. For retail investors, this means faster access to funds when selling shares and simpler portfolio management. For the company, it enhances liquidity and market accessibility, which can attract institutional investors and support capital raising efforts. In the broader context of OTC markets, such infrastructure improvements signal maturation and increased investor protection, potentially leading to better valuation and reduced volatility. As Synbio advances its AI-driven medical diagnostics platform, efficient trading infrastructure becomes crucial for executing strategic partnerships and financing activities that could accelerate development of healthcare technologies affecting patient outcomes.
Summary
Synbio International Inc. (OTC: SYIN), a medical research and technology company focused on AI-driven medical diagnostics, has achieved a significant milestone in modernizing its trading infrastructure. The company announced approval for Deposit/Withdrawal at Custodian (DWAC) and Direct Registration System (DRS) processing through its transfer agent, Pacific Stock Transfer Company. This development enables electronic share transfers between broker-dealers and the transfer agent, eliminating physical certificates, reducing settlement times, and lowering transaction friction for more efficient trading. DRS allows shareholders to hold shares directly on the company's books electronically, providing greater control, enhanced security, and simplified transferability without intermediary custody.
CEO Claudio Solitario emphasized that achieving DWAC and DRS eligibility represents a foundational step in strengthening Synbio's capital markets platform, positioning the company to move quickly on near-term initiatives. This modernization effort comes as Synbio transitions toward a more investor-ready, execution-focused public company platform, with multiple near-term capital markets and operational catalysts expected. The company, which aims to bridge the gap between wellness and medicine through strategic partnerships and research collaborations, views this development as critical for making its stock easily accessible and efficiently tradable for the investment community as it advances strategic initiatives including planned financing activities and partnership developments.
The announcement, distributed through NEWMEDIAWIRE, represents an important step in Synbio's ongoing efforts to improve accessibility for both existing shareholders and prospective investors. By eliminating the need for physical share certificates and enabling electronic processing, the company reduces barriers to trading while providing investors with enhanced ownership security and control. This infrastructure upgrade supports Synbio's broader mission of developing science-based solutions that improve quality of life and empower healthcare providers through clinically validated AI-driven medical diagnostics, positioning the company for more efficient execution of its strategic initiatives in the evolving healthcare technology landscape.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Synbio International Modernizes Trading with DWAC/DRS Approval
